JWJie Wu

Jie Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jie Wu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Xia Zhou

    State International Joint Research Center for Animal Health Breeding, College of Animal Science and Technology, Shihezi University, Shihezi 832003, China

    2 shared publications
  • Cai-Hong Zhao

    College of Animal Science and Technology, State International Joint Research Center for Animal Health Breeding, Shihezi University, Shihezi 832003, China

    1 shared publication
  • Hongsu He

    College of Animal Science and Technology, Shihezi University, Shihezi 832003, China

    1 shared publication
  • Hui Zhang

    College of Animal Science and Technology, Shihezi University, Shihezi, China

    1 shared publication
  • Hui Zhang

    State International Joint Research Center for Animal Health Breeding, College of Animal Science and Technology, Shihezi University, Shihezi 832003, China

    1 shared publication
  • Jia Guo

    State International Joint Research Center for Animal Health Breeding, College of Animal Science and Technology, Shihezi University, Shihezi 832000, China

    1 shared publication

Latest Publications

  • Open Access

    Antigenicity analysis of the recombinant fusion proteins NlpI of Mannheimia haemolytica and DsbA of Pasteurella multocida

    by Shuyun Xu, Yingni Sun, Jingjing Wei, Zengke Wei, Jie Yu, Meiqi Jiang, Hui Zhang, Zhihua Sun, Zhen Wang, Zijie Wang, et al.

    To analyze the antigenic characteristics of the recombinant fusion proteins rNlpI-DsbA (rND) of bovine Mannheimia haemolytica and Pasteurella multocida, re

  • Open Access

    Antigenicity analysis of the recombinant outer membrane NlpI protein of Mannheimia haemolytica

    by Xu Shuyun, Sun Yingni, Wei Jingjing, Wei Zengke, Yu Jie, Jiang Meiqi, Luo Chaofan, Zhang Hui, Wang Zhen, Wang Zijie, et al.

    To explore the antigenic characteristics of the NlpI protein. This study screened a potential antigen of Mannheimia haemolytica using NCBI Blast analysis and investigated its immunogenicity using online software. The recombinant NlpI protein (rNlpI) was expressed in prokaryotic cells, and its reactogenicity was detected by western blot. The transcription level of nlpI mRNA in M. haemolytica after various culture durations was determined by RT-qPCR. Mice were challenged with M. haemolytica strain 95 at an LD50 dose, and their serum was collected at various times. The rNlpI protein in M. haemolytica and western blot were used to detect the expression of antibodies specific to rNlpI. BALB/c mice were immunized with various protein doses and white oil adjuvant on days 0, 7, and 14, and the antibody titer was detected by indirect ELISA. Cytokines were detected by double antibody sandwich ELISA. Seven days after the third immunization, M. haemolytica strain 95 was injected intraperitoneally at 3 × 108 CFU/mouse. After 48 h, the surviving mice were dissected and the bacterial load in their lungs was assessed. NlpI is a hydrophilic and soluble protein with a transmembrane domain, 11 antigenic determinants, and 27 B cell epitopes. It was speculated that the protein has strong immunogenicity. The expressed NlpI protein could bind to bovine serum positive for M. haemolytica. The transcription level of the nlpI gene was the highest in the stable phase, followed in decreasing order by the logarithmic, slow, and decline phases. The expression levels in the various phases differed insignificantly. The IgG antibody titers of mice immunized with 10, 20, and 30 µg NlpI + white oil adjuvant and 30 µg NlpI were measured. The antibody level of the 30 µg NlpI + white oil adjuvant group was higher than that in the other groups (P < 0.001). The immune protection rates of the 10 µg rNlpI + white oil adjuvant and 30 µg rNlpI groups were under 30%, while they were 50% and 60%, respectively, in the 20 and 30 µg rNlpI + white oil adjuvant groups. The bacterial load of all immunized groups was 99.99% lower than in the PBS and white oil adjuvant control groups. The protection rates differed significantly among immunized groups (P < 0.001), with the 30 µg rNlpI + white oil adjuvant group showing the lowest bacterial load in the lungs. The rNlpI protein can react with bovine M. haemolytica positive blood with good reactogenicity, and can induce mice to produce high titers of specific IgG antibodies, effectively resisting homologous strain invasion. The results lay a good foundation for developing new M. haemolytica vaccines.

  • Open Access

    Assessment of Biodegradation Mechanisms of Ceftiofur Sodium by Escherichia sp. CS-1 and Insights from Transcriptomic Analysis

    by Meng-Yang Yan, Cai-Hong Zhao, Jie Wu, Adil Mohammad, Yi-Tao Li, Liang-Bo Liu, Yi-Bo Cao, Xing-Mei Deng, Jia Guo, Hui Zhang, et al.

    Ceftiofur sodium (CFS) is a clinically significant cephalosporin widely used in the livestock and poultry industries. However, CFS that is not absorbed by animals is excreted in feces, entering the environment and contributing to the emergence of antibiotic-resistant bacteria (ARB) and antibiotic-resistant genes (ARGs). This situation poses substantial challenges to both environmental integrity and public health. Currently, research on the biodegradation of CFS is limited. In this study, we isolated a strain of Escherichia coli, designated E. coli CS-1, a Gram-negative, rod-shaped bacterium capable of utilizing CFS as its sole carbon source, from fecal samples collected from hog farms. We investigated the effects of initial CFS concentration, pH, temperature, and inoculum size on the degradation of CFS by E. coli CS-1 through a series of single-factor experiments conducted under aerobic conditions. The results indicated that E. coli CS-1 achieved the highest CFS degradation rate under the following optimal conditions: an initial CFS concentration of 50 mg/L, a pH of 7.0, a temperature of 37 °C, and an inoculum size of 6% (volume fraction). Under these conditions, E. coli CS-1 was able to completely degrade CFS within 60 h. Additionally, E. coli CS-1 exhibited significant capabilities for CFS degradation. In this study, six major degradation products of (CFS) were identified by UPLC–MS/MS: desfuroyl ceftiofur, 5-hydroxymethyl-2-furaldehyde, 7-aminodesacetoxycephalosporanic acid, 5-hydroxy-2-furoic acid, 2-furoic acid, and CEF-aldehyde. Based on these findings, two degradation pathways are proposed. Pathway I: CFS is hydrolyzed to break the sulfur–carbon (S–C) bond, generating two products. These products undergo subsequent hydrolysis and redox reactions for gradual transformation. Pathway II: The β-lactam bond of CFS is enzymatically cleaved, forming CEF-aldehyde as the primary degradation product, which is consistent with the biodegradation mechanism of most β-lactam antibiotics via β-lactam ring cleavage. Transcriptome sequencing revealed that 758 genes essential for degradation were upregulated in response to the hydrolysis and redox processes associated with CFS. Furthermore, the differentially expressed genes (DEGs) of E. coli CS-1 were functionally annotated using a combination of genomics and bioinformatics approaches. This study highlights the potential of E. coli CS-1 to degrade CFS in the environment and proposes hypotheses regarding the possible biodegradation mechanisms of CFS for future research.